Thrombin generation assay:  a new tool to predict and optimize clinical outcome in cardiovascular patients?
Antithrombotic therapy (including antiplatelet and anticoagulant drugs) is the cornerstone of the current medical treatment of patients with acute coronary syndromes (ACS). This therapy and particularly the new antiplatelet and anticoagulant drugs have significantly reduced the ischemic risk, but have increased bleeding complications. Recently, several studies have emphasized the negative prognostic impact on long-term mortality of these bleeding adverse events. Thus, new assays to estimate the bleeding risk and the efficacy of these antithrombotic drugs are clearly in demand. Regarding the anticoagulant drugs, new promising data have emerged about the thrombin generation assay (TGA). TGA measures the ability of plasma to generate thrombin. TGA may be used to check coagulation function, to value risk of thrombosis and to compare the efficacy of different anticoagulants employed in clinical management of patients with ACS. The TGA result is a curve which describes the variation of thrombin's amount during the activation of the coagulation cascade. All available anticoagulant drugs influence the principal parameters generated by TGA and so it is possible to evaluate the effects of the medical treatment. In this review we provide a brief description of the assay and we summarize the principals of previous studies by analyzing the relationship between anticoagulant drugs and TGA. Moreover, a brief summary of its ability to predict ischemic and bleeding risks has been provided.
Cardiovascular Institute, Azienda Ospedaliero-Universitaria S Anna, Lumezzane, BS, Italy. cmpglc@unife.it
Gianluca
G
Campo
Rita
R
Pavasini
Alberto
A
Pollina
Luca
L
Fileti
Jlenia
J
Marchesini
Matteo
M
Tebaldi
Roberto
R
Ferrari
D054058:Acute Coronary Syndrome / Q000175:diagnosis / Q000188:drug therapy*; D000991:Antithrombins / Q000494:pharmacology / Q000627:therapeutic use; D001681:Biological Assay; D005343:Fibrinolytic Agents / Q000494:pharmacology / Q000627:therapeutic use; D006470:Hemorrhage / Q000175:diagnosis / Q000517:prevention & control*; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D011237:Predictive Value of Tests; D013917:Thrombin / Q000037:antagonists & inhibitors / Q000096:biosynthesis*; D013927:Thrombosis / Q000175:diagnosis / Q000517:prevention & control*; D016896:Treatment Outcome
D000991:Antithrombins; D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D013917:Thrombin